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Abstract Previous evidence from our laboratory showed
that Epstein–Barr virus–immortalized lymphoblastoid B
cells undergo a prominent down-modulation of HLA-II
molecule expression when injected intraperitoneally in
SCID mice, while HLA-I remains almost unaVected. Since
this phenomenon can alter the experimental outcome of
therapeutic protocols of adoptive cell therapy, we decided
to evaluate the behavior of MHC antigens in a panel of cell
lines belonging to the B- and T-cell lineages, as well as in
epithelial tumor cell lines. Cells were administered in mice
either intraperitoneally or subcutaneously and recovered
4 days later for HLA molecule expression analysis. Col-
lected data showed a highly heterogeneous in vivo behavior
of the various cell lines, which could alternatively down-
modulate, completely abrogate or maintain unchanged the
expression of either MHC-I or MHC-II molecules. More-
over, the site of injection impacted diVerentially on these
aspects. Although such phenomena still lack a comprehen-
sive clariWcation, epigenetic mechanisms are likely to be
involved as epigenetic drugs could partially counteract
MHC down-modulation in vivo. Nonetheless, it has to be
pointed out that careful attention must be paid to the assess-
ment of therapeutic eYcacy of translational protocols of
adoptive immunotherapy, as modulation of MHC mole-
cules on human target cells when transferred in a mouse
environment could readily interfere with the desired and
expected therapeutic eVects.
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Introduction
The use of pre-clinical mouse models represents a common
approach exploited to validate laboratory observations in
vivo. These models allow to study disease states in ways
that would be unfeasible in human patients or that would
imply harm to be inXicted on humans.
In particular, the use of immunosuppressed mice inocu-
lated with human tumor cell lines is widely exploited in
tumor immunology, where they are used to test the eVects
of diVerent therapeutic approaches, including protocols of
adoptive cell therapy (ACT). In this regard, we previously
reported results of pre-clinical ACT immunotherapy
employing cytolytic CD4+ T cells directed to Epstein–Barr
virus (EBV) antigens [1]. While these populations exerted a
very relevant in vitro MHC-II–restricted cytotoxic activity
against autologous EBV-transformed lymphoblastoid cell
lines (LCL), nonetheless they disclosed a reduced in vivo
eYcacy in comparison with their CD8+ EBV-speciWc coun-
terpart. We found that expression of HLA-II molecules on
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LCL underwent a rapid down-modulation upon in vivo
transfer. This phenomenon could be reverted by the in vivo
use of a demethylating agent (decitabine) that signiWcantly
restored the HLA-II expression on LCL [1].
Here, we extended the analysis of the expression of
MHC antigens on a panel of diVerent cell lines after ex vivo
recovery following either subcutaneous (s.c.) or intraperito-
neal (i.p.) administration, as such markers are critically
involved in the interaction between eVector and target cells,
and therefore, their modulation could strongly impact on
the results of the experimental approaches of ACT.
Our results indicate that diVerent cell lines behave diVer-
ently and that even the site of injection can inXuence the
expression of HLA molecules in vivo. Since the expression
of MHC-I and MHC-II can be under epigenetic control [2],
we assessed these aspects in our model using epigenetic
drugs in vivo. Here, we provide evidence that one of the
potential reasons for the observed down-modulation relies
on epigenetic mechanisms, likely activated by the mouse
microenvironment.
Based on these observations, we suggest that any ACT
approach involving human tumor cell lines transferred in a
mouse environment should be preceded by a careful analy-
sis of MHC expression along tumor growth in vivo, since
HLA antigen down-modulation could introduce a strong
bias in the assessment of therapeutic eYcacy of adoptively
transferred eVector T cells.
Materials and methods
Cell lines
The following human cell lines were used: DG-75, Daudi,
Namalwa, and BL-41 are Burkitt lymphoma B cell lines;
BL-41 B95.8 is the EBV-infected counterpart cell line; Raji
is a lymphoblast-like cell line derived from a Burkitt’s lym-
phoma; LCL is a lymphoblastoid cell line generated by
EBV infection of PBMC; SH-9 is a lymphoblastoid cell
line that spontaneously immortalized and derived from a
Hodgkin’s lymphoma patient; HuT-78 and Jurkat are T cell
lymphoma cell lines; MOLT-3 and CEM are acute lympho-
blastic leukemia T cell lines; IGROV-1 and OVCAR-3 are
ovary adenocarcinoma cell lines; SK23-Mel, UACC-257,
and A375 are malignant melanoma cell lines.
In vivo experiments
Six- to 8-week-old female SCID mice were purchased from
Charles River Laboratories (Calco, Italy) and housed in our
speciWc pathogen-free animal facility. Procedures involving
animals and their care were in conformity with institutional
guidelines (D.L. 116/92 and subsequent complementing
circulars), and all experimental protocols were approved by
the local ethical committee of Padova University (CEASA).
A total of 80–100 £ 106 cells from every cell line were
injected i.p., while 20–25 £ 106 cells were used for s.c.
injection. Four days later, the subcutaneous masses were
recovered, mechanically disaggregated, and used for immu-
nophenotyping. Similarly, i.p. injected cells were recovered
by peritoneal washing and used for the Xow cytometry
analyses. A high number of cells were required for the ini-
tial injection to provide the recovery of suYcient cells for
subsequent staining and in vitro culture.
In vitro and in vivo treatment with epigenetic drugs
Tumor cells explanted ex vivo were cultured in vitro with
diVerent epigenetic drugs (trichostatin A and decitabine,
also known as 2-deoxy-5-azacytidine) that had already
proven to be eVective in vitro [3, 4] or in vivo [1]. Cells
were plated at 5 £ 105 cells/well in 24-well plate in com-
plete medium (control) or medium added with trichostatin
A (50, 250, and 500 nM, Sigma) or decitabine (1 M,
Pharmachemie B.V., Haarlem, Holland), for up to 72 h. For
in vivo experiments, mice were treated with trichostatin A
(1 mg/kg once a day, days 0–3, Sigma [5]), decitabine
(0.25 mg/kg once at day 0, then twice a day, days 1–3 [1]),
suberoylanilide hydroxamic acid (SAHA, 1.25 mg/mouse,
once a day, days 1–3, Alexis Biochemicals, Lausen, Swit-
zerland [6]), valproic acid (5 mg/mouse, once a day, days
1–3, modiWed from [7], Sigma), and Interferon-
(50,000 IU/mouse, once, 6 h before cells recovery, modi-
Wed from [1], PeproTech, Rocky Hill, NJ). On day 4, cells
were recovered by peritoneal washing and used for the Xow
cytometry analyses.
Flow cytometry analysis
Human cancer cells recovered ex vivo were initially gated
according to their forward- and side-scatter proWles and
then speciWcally identiWed for their human origin with anti-
bodies to CD5 (for the MOLT-3 cell line; clone MEM-32,
ImmunoTools, Friesoythe, Germany), CD19 (for all the B
cell lines; clone 89B, Coulter, Milano, Italy), CD45 (for all
the T cell lines, but MOLT-3; clone MEM-28, Immuno-
Tools), and CD44 antibody (for all the epithelial cancer cell
lines; clone J-173, Immunotech Coulter, Milano, Italy). The
gated populations always conWrmed to be 100% positive
for the respective markers.
Further stainings were performed with antibodies to
2-microglobulin (clone 2M2, BioLegend, Cambridge,
UK), HLA-I (HLA-A, HLA-B, and HLA-C loci, clone
W6/32, BioLegend), HLA-A2 (clone BB7.2, BioLegend),
HLA-II (clone Tü39, BD, Erembodegem, Belgium),
HLA-DR (clone L243, BD; clone LN3, eBiosciences,Cancer Immunol Immunother (2011) 60:1639–1645 1641
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San Diego, California, USA), HLA-DQ (clone HLADQ1,
BioLegend; clone Tu169, BD), and PAN-Ig (Goat poly-
clonal anti-human IgG, IgA, and IgM (H+L), AbD Serotec,
Oxford, UK). Control stainings were performed using the
appropriate isotypes (mouse IgG1 for 2-microglobulin
and HLA-DQ, BD; goat IgG for PAN-Ig, AbD Serotec;
mouse IgG2a for all the other antibodies, BD).
To avoid potential bias in recognizing the implanted
human cell lines, all antibodies were tested for cross-reac-
tivity with mouse splenocytes and found negative.
After staining, red blood cells were lysed and cells were
analyzed using FACSCalibur (BD) instrument and FlowJo
software (TreeStar Inc., Olten, Switzerland).
Percentage of positivity was calculated as the diVerence
between the positivity percentage of each marker and that
of the corresponding isotype control.
Results
Based on our previous results [1], Wrst we decided to extend
the assessment of MHC-I and MHC-II expression, before in
vivo administration and after ex vivo recovery, to a panel of
B cell lines. Such analysis revealed that in all cases the per-
centage of positivity and the mean Xuorescence intensity
(MFI) of samples were lower after ex vivo evaluation, but
no general rule could be inferred. DG-75, SH-9, Raji (this
latter being reported in Fig. 1a, b as an example of this
group of cells), and Daudi (which does not harbor MHC
class I) cell lines completely or partially down-modulated
HLA-I and HLA-II molecule expression when injected i.p.
On the other hand, most of the cell lines maintained a high
expression of the analyzed markers when injected s.c., with
the exception of LCL and, partially, SH9, Namalwa, and
Daudi cell lines (LCL and Namalwa illustrate this behavior
in Fig. 1b). The only B cell lines that preserved the expres-
sion of MHC-I and MHC-II markers, after both i.p. and s.c.
injection, were BL-41 and their EBV-infected counterpart
(Fig. 1a, b). Expression data obtained with pan anti-HLA-I
were fully conWrmed by staining recovered cells with anti-
2-microglobulin antibody (Fig. 1b) and anti-HLA-A2
allele-speciWc antibody (where present, data not shown).
Similarly, results of cytometry analyses with the use of
anti-HLA-DR and anti-HLA-DQ antibodies completely
overlapped those obtained with pan anti-HLA-II (data not
shown).
Interestingly, even the expression of surface immuno-
globulins underwent down-modulation when injected i.p.
(especially in Raji cell line), while it was generally main-
tained after s.c. injection (Fig. 1b).
When T cells were considered (Fig. 2a), it turned out
that the s.c. injection induced the partial down-modulation
of MHC-I on all the lines we studied, except MOLT-3. The
i.p. inoculation route aVected marker expression on MOLT-
3 and HuT-78 cells but did not inXuence Jurkat and CEM
cell lines. Finally, two ovarian carcinoma and three malig-
nant melanoma cell lines were tested: IGROV-1 and
OVCAR-3 tumors strongly down-modulated HLA-I
expression after either i.p. or s.c. injection, while all mela-
nomas retained MHC-I expression when injected i.p. but
lost it after s.c. administration. (Fig. 2b shows only SK23-
Mel, as an example of the behavior of the three melanoma
cell lines.) Again, also in the case of both T cell and epithe-
lial tumor cell lines, data of pan MHC-I and MHC-II
expression were conWrmed by staining with anti-2-micro-
globulin and allele-speciWc antibodies (Fig. 2a, b and data
not shown).
As some HLA-I and HLA-II promoters (and their trans-
activators) can be under epigenetic control [2], host and
tumor microenvironments might induce methylation and
histone deacetylation in tumor cells, thus aVecting the
expression of the MHC-I and MHC-II molecules [8, 9]. To
evaluate this possibility, we cultured tumor cells explanted
ex vivo with diVerent epigenetic drugs (namely, trichostatin
A and decitabine) that had already proven to be eVective in
vitro [3, 4] or in vivo [1], respectively. Surprisingly, we
observed that the simple placement of tumor cells in com-
plete medium, without the addition of any drug, led to
reversion of the down-modulated phenotype (when present)
within a few hours (data not shown). To better clarify this
issue, we decided to test the diVerent epigenetic drugs in
vivo, in parallel with interferon-, a well-known inducer of
MHC molecule expression. Mice were injected i.p. with
tumor cell lines and treated with trichostatin A, decitabine,
suberoylanilide hydroxamic acid, valproic acid, or Inter-
feron-. As it can be appreciated in online resource, Supple-
mental Figure, decitabine positively modulated HLA-II and
HLA-I expression on LCL cells, while the treatment with
trichostatin A partially restored the MHC-I expression on
the IGROV-1 cell line.
Discussion
Adoptive cell therapy is regarded as an eYcient and prom-
ising approach for the treatment of diVerent tumors, ranging
from several EBV-related malignancies [1,  10] to mela-
noma [11]. Before a new ACT protocol is accepted for clin-
ical use, its eYcacy has to be demonstrated in animal
models, mainly in mice injected with tumor cell lines to
simulate the disease. While these models are generally
accepted, notwithstanding they raise concerns regarding the
cytokine milieu, the tumor microenvironment, the inocula-
tion setting, and the life span of human-origin components
that are transferred into the mouse, which can give rise to
several biases ultimately perturbing the outcome [12, 13].1642 Cancer Immunol Immunother (2011) 60:1639–1645
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Fig. 1 a Representative cyto-
Xuorimetric analysis of DG-75, 
BL-41 B95.8, and Raji cell lines: 
expression of diVerent markers 
(HLA-I for DG-75 and BL-41 
B95.8 cells and HLA-II for Raji 
cell line) after i.p. (dotted line) 
or s.c. (dashed line) recovery in 
comparison with in vitro expres-
sion (black line). Gray areas 
represent the isotype controls. 
b HLA-I, 2-microglobulin 
(b2m), HLA-II, and immuno-
globulins (Ig) percentage of pos-
itivity (left panels) and MFI of 
expression (right panels) from 
selected B cell lines after i.p. and 
s.c. injection. White and black 
bars refer to values of cells 
recovered from i.p. and s.c. sites, 
respectively, while gray bars 
show data of cells maintained in 
in vitro culture. The percentage 
of positivity for in vitro markers 
expression is not shown and is 
always 100%. Figure shows 
mean § SD of at least 3 inde-
pendent experiments for each 
cell lineCancer Immunol Immunother (2011) 60:1639–1645 1643
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Fig. 2 a HLA-I, 2-microglob-
ulin (b2m), and HLA-II percent-
age of positivity and MFI of 
expression on diVerent T cell 
lines after i.p. and s.c. recovery. 
White and black bars refer to i.p. 
and s.c. injection, respectively, 
while gray bars refer to the in 
vitro condition. The percentage 
of positivity for in vitro markers 
expression is not shown and is 
always 100%. Figure shows 
mean § SD of at least 3 inde-
pendent experiments for each 
cell line. b CytoXuorimetric 
analysis of diVerent epithelial 
tumor cell lines. Bars as in 
a. Figure shows mean § SD of 
at least 3 independent experi-
ments for each cell line1644 Cancer Immunol Immunother (2011) 60:1639–1645
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An example of such aspects can be found in a previous
work from our group [1] where we assessed the therapeutic
potentiality of EBV-speciWc CD4+ cytotoxic T cells, which
were eVective in vitro, but not in vivo. We observed that
LCL target cells, when injected in SCID mice, underwent a
rapid HLA-II down-modulation, thus reducing the natural
recognition of MHC-II peptide complexes by CD4+ CTL.
Since this behavior was not observed in humans [1], we
concluded it was induced in the mouse model by some
unidentiWed stimuli that could be partially overcome by
using demethylating agents [1]. Based on such observation,
we wondered whether this phenomenon was limited to LCL
or could represent a more frequent occurrence. Therefore,
we Wrst extended the panel of B cell lines tested that were
analyzed 4 days after injection, because previous results
showed that the maximal down-modulation was already
reached at this time point [1] and maintained afterward
(data not shown): results indicated that a recurrent behavior
could not be established. Moreover, the site of injection had
a profound inXuence on the observed down-modulation. In
particular, with the exception of Namalwa, BL-41, and BL-
41 B95.8 cell lines, all the other B cell lines down-modu-
lated the expression of HLA-I and/or HLA-II when injected
i.p., while the s.c. inoculation negatively impacted only on
LCL, SH9, Daudi, and partially on Namalwa cell lines.
Notably, surface immunoglobulin expression was also
reduced in some cell lines and in a diVerential manner
according to the injection site, when recovered ex vivo in
comparison with in vitro culture.
Since no general rule could be extrapolated, we
expanded our analysis to some T cell lines: again, no coher-
ent behavior could be identiWed as HLA-I expression was
totally abrogated in MOLT-3 and HuT-78, but not in Jurkat
and CEM cell lines when injected intraperitoneally; the s.c.
injection induced a partial down-modulation on all T cell
lines, but the MOLT-3 cells. Finally, MHC class I expres-
sion on some epithelial tumor cell lines appeared undergo-
ing a constant down-modulation, but even in this case with
an exception represented by melanomas after i.p. injection.
Whereas the causes of such phenomena are not fully
clariWed yet, nonetheless epigenetic mechanisms are likely
to be involved, as supported by results we reported with
epigenetic drugs; indeed, decitabine partially restored
MHC-II expression in LCL cells, thus indicating that the
methylation of promoters of genetic elements involved in
the expression of HLA alleles may play an important role in
MHC down-modulation [1]. On the other hand, trichostatin
A counteracted HLA down-modulation in IGROV-1 cells,
a Wnding suggesting that histone acetylation may represent
an additional relevant mechanism, as previously reported in
a diVerent setting [3]. These data are also in line with a pre-
vious study reporting an epigenetic eVect of the microenvi-
ronment, where bystander stromal cells may have a major
inXuence on the growth and progression of tumors [14].
Moreover, in both the peritoneal cavity and, more pro-
nouncedly, the inner mass of subcutaneous inoculi, tumor
cells might undergo an hypoxic state, which has been
already demonstrated to down-modulate HLA-G and
MHC-I–related chain A (MICA) [15, 16]; further, hypoxia
has been also directly involved in MHC-I and MHC-II
down-modulation in rat cells [17].
In conclusion, no general rule regarding the maintenance
or down-modulation of MHC-I or MHC-II molecules on
human tumor cell lines upon in vivo transfer in immunode-
Wcient mice can be inferred by our data; indeed, every cell
line appears to possess a particular behavior. These obser-
vations raise some important concerns about the interpreta-
tion of data resulting from the administration of human T
cells into human-tumor-bearing mice, since negative results
can be due to the absence of target molecules on the surface
of cancer cells. Overall, our suggestion is therefore to check
carefully the expression of MHC antigens on tumor cell
lines upon their in vivo transfer before testing an ACT ther-
apeutic protocol.
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